Highest-materiality recent filing
Nu Skin Q2 revenue down 17% to $320M; GAAP EPS -$5.14, adjusted $0.20
Revenue $320.1M, down 17.1% YoY; FX impact -$4.0M.
Nu Skin Q1 revenue $320.6M (-12% YoY), EPS $0.04; guides FY rev $1.35-1.50B
Q1 revenue $320.6M, -12% YoY (1.1% FX tailwind); GAAP EPS $0.04, adjusted EPS $0.14 vs $0.23 prior.
Nu Skin CFO James Thomas resigns; Chelsea Lantz named Interim CFO
James Thomas resigned as EVP and CFO effective March 17, 2026, to pursue an outside opportunity.
Nu Skin Q4 revenue $370.3M (-16.9% YoY); FY2025 EPS $3.18, adj. $1.27; Q1 2026 outlook weak
Q4 2025 revenue $370.3M, down 16.9% YoY; EPS $0.29 vs $(0.73) prior year.
Nu Skin Q3 revenue $364.2M (-15.3% YoY); EPS $0.34 in line with guidance
Revenue $364.2M, down 15.3% YoY (down 11.5% ex-Mavely); EPS $0.34 vs $0.17 prior year.
Nu Skin Q2 EPS $0.43 beats guidance; raises FY EPS outlook to $3.05-$3.25
Revenue $386.1M, down 12% YoY; EPS $0.43 (adj. $0.21) vs ($2.38) prior year.
Nu Skin Q1 revenue $364.5M at high end of guidance; adj EPS $0.23 excl. Mavely gain
Q1 revenue $364.5M (-12.7% YoY, ~3% FX headwind); GAAP EPS $2.14 includes $176.2M Mavely gain; adjusted EPS $0.23.
Nu Skin Q4 revenue $445.6M, beat guidance; full-year 2025 revenue outlook $1.48-1.62B
Q4 GAAP EPS $(0.73); adjusted EPS $0.38 vs $0.37 prior year; revenue down 8.8% YoY.
Nu Skin Q4 prelim revenue at high end of guidance; closed Mavely deal for $250M
Q4 2024 preliminary revenue at high end of company's guidance range.
Nu Skin sells Mavely to Later for $250M; expects ~$207M cash, $10M stock after distributions
Total consideration $230M cash plus $20M in Purchaser common stock; closed January 2, 2025.
Nu Skin Q3 revenue $430.1M (-13.8% YoY), EPS $0.17; guides lower Q4/FY
Q3 revenue $430.1M (-13.8% YoY); customers 831,768 (-15%), paid affiliates 149,264 (-20%).
Revenue $439.1M, down 12.2% YoY; FX headwind of 4.2% ($21.0M).
Nu Skin Q1 revenue $417.3M, down 13%; EPS $(0.01) GAAP; customer base shrinks 19%
Revenue $417.3M, down 13.3% YoY; foreign currency hit of $18.2M; Rhyz revenue up 57.5% to $62.5M.
Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B
Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.
Nu Skin Q3 revenue down 7% to $498.8M; GAAP EPS $(0.74); guides FY23 revenue $1.92-1.96B
Q3 revenue $498.8M vs $537.8M prior; GAAP EPS loss $(0.74) including $65.7M inventory write-off.
Nu Skin Q2 revenue $500.3M, down 11% YoY; EPS $0.54; acquires BeautyBio
Revenue $500.3M, -11% YoY; EPS $0.54 vs $0.67 prior year (or $0.77 ex-Grow Tech charges).
Nu Skin Q1 2023 revenue $481.5M (-20% YoY), EPS $0.23 vs $0.76; reaffirms FY guidance
Revenue fell 20% to $481.5M; GAAP EPS $0.23 declined from $0.76; adjusted EPS $0.37 ex restructuring.
Nu Skin CFO Mark Lawrence resigns; James Thomas named Interim CFO
Mark Lawrence resigns as EVP and CFO effective March 31, 2023; will remain as senior advisor through April.
Nu Skin Q4 revenue down 22% to $522.3M; guides Q1 rev $450-490M
Q4 revenue $522.3M (-22% YoY); full-year $2.23B (-17%); customers fell 16% to 1.15M.
Nu Skin Q3 2022 revenue $537.8M (-16% YoY); GAAP EPS $(0.51), non-GAAP $0.47
Revenue $537.8M, down 16% YoY (7% FX headwind); gross margin 67.7% (72.7% ex-restructuring).
Nu Skin Q2 revenue falls 20% to $560.6M; cuts FY guidance, plans restructuring
Revenue of $560.6M, down 20% YoY; adjusted EPS of $0.77 (ex. Grow Tech) vs $1.15 prior year.
Nu Skin prelim Q2 revenue $557-562M, soft due to China COVID, EMEA conflict
Estimated Q2 2022 revenue between $557 and $562 million, softer than expected.
Nu Skin enters into $900M credit facility; $400M term loan + $500M revolver, 5-year term
New credit agreement provides a $400M term loan and a $500M revolving credit facility, each with a five-year term.
Nu Skin Q1 revenue $604.9M (-11% YoY), EPS $0.76 (-16%); lowers FY22 guidance
Revenue $604.9M, down 11% YoY; EPS $0.76 vs $0.91; gross margin 73.3% vs 74.8%.
Nu Skin reports 2021 adjusted EPS up 14% to $4.14; revenue up 4%; unveils Nu Vision 2025 plan
Total revenue increased 4% in 2021; adjusted EPS grew 14% to $4.14 (reported EPS down 21% to $2.86 due to restructuring).
Nu Skin Q4 rev $673M (-10%), adj EPS $1.11; FY22 guidance rev $2.66-2.77B, EPS $4.05-4.45
Q4 2021 revenue $673.4M, down 10% YoY; customers down 12% to 1.37M, sales leaders down 13% to 61,515.
Nu Skin to exit Grow Tech segment, expects $52-60M in pre-tax charges
Decision to wind down controlled-environment agriculture business, focused on feed industry.
Nu Skin Q3 revenue $641.2M (-9% YoY), EPS $0.97 (-10%); cuts Q4 outlook
Q3 revenue $641.2M, down 9% YoY; EPS $0.97 vs $1.08 in prior year.
Nu Skin estimates Q3 revenue $637-642M, below expectations due to delta variant disruptions
Estimated Q3 2021 revenue between $637M and $642M, softer than anticipated.
Nu Skin Q2 revenue $704.1M, EPS $1.15 (+42% YoY), raises FY EPS guidance
Revenue $704.1M (+15% YoY, +6% FX); EPS $1.15 vs $0.81 prior year (+42%).
Steven K. Hatchett notified the Company that, due to family health circumstances, he determined to resign from his position as Executive Vice President and Chief Product Officer, effective as of May 8, 2026.
On March 5, 2025, Zheqing (Simon) Shen informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided not to stand for re-election to the Company’s Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders due to other professional commitments.
On September 10, 2024, the Board of Directors (the “Board”) of Nu Skin Enterprises, Inc. (the “Company”) appointed Mark A. Zorko as a director of the Company
On March 15, 2024, Andrew Lipman informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided to retire from the Company’s Board of Directors (the “Board”) and will not stand for re-election to the Board at the Company’s 2024 Annual Meeting of Stockholders.
Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.
Connie Tang notified the Company that, due to family health reasons, she determined to resign from her position as Executive Vice President and Chief Global Growth and Customer Experience Officer, effective October 31, 2023.
On July 24, 2023, following a search that included internal and external candidates, the Company’s Board of Directors appointed James D. Thomas as Executive Vice President and Chief Financial Officer on a permanent basis.
On March 24, 2023, Mark H. Lawrence notified Nu Skin Enterprises, Inc. (the “Company”) of his resignation from his position as Executive Vice President and Chief Financial Officer.
On March 30, 2023, the Company’s Board of Directors appointed James D. Thomas, the Company’s Senior Vice President and Chief Accounting Officer, as Interim CFO, effective upon Mr. Lawrence’s departure as CFO.
Max materiality 0.85 · Median 0.65 · Most common event earnings